# Obesity Guideline (synthetic summary)
- Pharmacotherapy is reasonable for BMI ≥30 or ≥27 with weight-related comorbidities when lifestyle measures are insufficient.
- GLP-1 RAs (e.g., semaglutide 2.4 mg) show meaningful weight loss with diet and exercise support.
- Assess contraindications; monitor weight, BMI, and adverse effects at regular intervals.
